Evidence map›Paper›PMID 40598771›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2025

Epigen-mediated mechanisms to alleviate glucose homeostasis disruptions in diet-induced obese and STZ-induced diabetic mice.

Ka-Ying Chan, Chu-Jun Deng, Dilun Chen, Tak-Ho Lo, Shiqi Jia, Pauline Po Yee Lui, Chi-Ming Wong

Abstract read
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. The novel adipokine Placin regulates glucose homeostasis via insulin secretion and IGF1 receptor signaling.Molecular therapy : the journal of the American Society of Gene Therapy · 2026
    Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ka-Ying ChanDepartment of Health Informatics and Technology, The Hong Kong Polytechnic University, Hong Kong SAR, China.
Chu-Jun DengDepartment of Health Informatics and Technology, The Hong Kong Polytechnic University, Hong Kong SAR, China.
Dilun ChenDepartment of General Surgery Ward II, Foshan Sanshui District People's Hospital, Foshan, Guangdong Province, China.
Tak-Ho LoDepartment of Health Informatics and Technology, The Hong Kong Polytechnic University, Hong Kong SAR, China; School of Life Science, The Guangzhou University, Guangzhou, Guangdong Province, China.
Shiqi JiaInstitutes of Biomedical Sciences, Inner Mongolia University, Hohhot, Inner Mongolia AR, China.
Pauline Po Yee LuiDepartment of Orthopaedics and Traumatology, Chinese University of Hong Kong, Hong Kong SAR, China.
Chi-Ming WongDepartment of Health Informatics and Technology, The Hong Kong Polytechnic University, Hong Kong SAR, China; State Key Laboratory of Pharmaceutical Biotechnology, University of Hong Kong, Hong Kong SAR, China; Shenzhen Research Institute, The Hong Kong Polytechnic University, Shenzhen, China. Electronic address: chi-ming.cm.wong@polyu.edu.hk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epidermal growth factor receptor (EGFR) plays a crucial role in cellular processes such as development and tissue repair, with dysregulation linked to various diseases, including those affecting energy metabolism. Previous studies have reported that EGFR ligands enhance glucose homeostasis through various mechanisms across different tissues. However, epigen, the latest EGFR ligand, has not been thoroughly investigated regarding its impact on energy metabolism. In this study, we employed both in vivo gain-of-function and loss-of-function approaches to investigate the role of epigen in metabolic regulation using diet-induced obesity (DIO) and streptozotocin (STZ)-induced diabetic mice. Our findings, which align with previous research on other EGFR ligands, provide the first evidence that epigen is crucial for glucose homeostasis. It promotes the release of endogenous insulin, enhances glucose uptake in adipose tissues and muscle, improves glycolysis and respiration utilization in adipose tissues of DIO mice, and increases pancreatic beta cell mass in STZ-induced diabetic mice. Overall, our findings suggest that epigen could be a potential therapeutic target for managing both type 2 and type 1 diabetes, warranting further exploration in clinical settings.

Indexed as

Diabetes Mellitus, ExperimentalGlucoseHomeostasisObesityAdipose TissueAnimalsDiet, High-FatDisease Models, AnimalEnergy MetabolismErbB ReceptorsGlycolysisInsulinMaleMiceMice, Inbred C57BLErbB ReceptorsGlucoseInsulindiabetesEGFRepigenglucose metabolisminsulin secretionobesity

Identifiers

PMID40598771
PMCPMC12628056

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.